<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30034236</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>08</Month>            <Day>17</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>17</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1178-2013</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>13</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>International journal of nanomedicine</Title>                <ISOAbbreviation>Int J Nanomedicine</ISOAbbreviation>            </Journal>            <ArticleTitle>Nanostructured lipid carriers co-delivering lapachone and doxorubicin for overcoming multidrug resistance in breast cancer therapy.</ArticleTitle>            <Pagination>                <MedlinePgn>4107-4119</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.2147/IJN.S163929</ELocationID>            <Abstract>                <AbstractText Label="Background" NlmCategory="UNASSIGNED">Multidrug resistance is responsible for the poor outcome in breast cancer therapy. Lapa is a novel therapeutic agent that generates ROS through the catalysis of the NAD(P) H:quinone oxidoreductase-1 (NQO1) enzyme which significantly facilitate the intracellular accumulation of the co-delivered DOX to overcome MDR in cancer cells.</AbstractText>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">Herein, in our study, nanostructured lipid carrier (NLC) co-delivering Î²-lapachone (Lapa) and doxorubicin (DOX) was developed (LDNLC) with the aim to overcome the multidrug resistance (MDR) in breast cancer therapy.</AbstractText>                <AbstractText Label="Patients and methods" NlmCategory="UNASSIGNED">Lapa and DOX were loaded into NLC to prepare LDNLC using melted ultrasonic dispersion method.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">The well designed LDNLC was nanoscaled particles that exhibited preferable stability in physiological environment. In vitro cell experiments on MCF-7 ADR cells showed increased DOX retention as compared to DOX mono-delivery NLC (DNLC). In vivo anti-cancer assays on MCF-7 ADR tumor bearing mice model also revealed significantly enhanced efficacy of LDNLC than mono-delivery NLCs (DNLC and LNLC).</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">LDNLC might be a promising platform for effective breast cancer therapy.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Xin</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Breast and Thyroid Surgery, Heze Municipal Hospital, Heze, Shandong, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jia</LastName>                    <ForeName>Xiaoqian</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery 2, The Fourth People's Hospital of Jinan, Jinan, Shandong, China, niuhu0678@126.com.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Niu</LastName>                    <ForeName>Hu</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of General Surgery 2, The Fourth People's Hospital of Jinan, Jinan, Shandong, China, niuhu0678@126.com.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>12</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>New Zealand</Country>            <MedlineTA>Int J Nanomedicine</MedlineTA>            <NlmUniqueID>101263847</NlmUniqueID>            <ISSNLinking>1176-9114</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D003102">Colloids</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D008055">Lipids</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009285">Naphthoquinones</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>4707-32-8</RegistryNumber>                <NameOfSubstance UI="C014638">beta-lapachone</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>80168379AG</RegistryNumber>                <NameOfSubstance UI="D004317">Doxorubicin</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>8L70Q75FXE</RegistryNumber>                <NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Colloids Surf B Biointerfaces. 2007 Nov 15;60(2):174-9</RefSource>                <PMID Version="1">17656075</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Chemother Pharmacol. 2005 Jan;55(1):12-20</RefSource>                <PMID Version="1">15365767</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Eur J Pharm Biopharm. 2014 Jan;86(1):7-22</RefSource>                <PMID Version="1">24007657</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>N Engl J Med. 2012 Nov 8;367(19):1783-91</RefSource>                <PMID Version="1">23020162</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Mater. 2017 Oct;29(38):</RefSource>                <PMID Version="1">28833669</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Control Release. 2015 Feb 28;200:201-11</RefSource>                <PMID Version="1">25542645</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Drug Deliv. 2016 May;23(4):1398-403</RefSource>                <PMID Version="1">26079530</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Ther Med. 2017 Oct;14(4):3407-3412</RefSource>                <PMID Version="1">29042926</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Jpn J Cancer Res. 2002 Feb;93(2):209-15</RefSource>                <PMID Version="1">11856485</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncol Rep. 2010 May;23(5):1469-75</RefSource>                <PMID Version="1">20372866</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Pharm. 2015 Nov 2;12(11):3999-4010</RefSource>                <PMID Version="1">26415823</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1999 Jan 15;59(2):391-8</RefSource>                <PMID Version="1">9927052</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Nanomedicine. 2015 Jan 06;10:305-20</RefSource>                <PMID Version="1">25609946</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Anticancer Drugs. 2003 Nov;14(10):845-50</RefSource>                <PMID Version="1">14597880</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Biochem Pharmacol. 2010 Nov 15;80(10):1497-506</RefSource>                <PMID Version="1">20696137</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Mater Chem B. 2016 May 7;4(17):2954-2962</RefSource>                <PMID Version="1">27152196</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2009 May 1;69(9):3918-26</RefSource>                <PMID Version="1">19383919</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Mater. 2016 Mar 9;28(10):1963-9</RefSource>                <PMID Version="1">26743228</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Ther Med. 2017 Sep;14(3):2071-2077</RefSource>                <PMID Version="1">28962126</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1995 Sep 1;55(17):3706-11</RefSource>                <PMID Version="1">7641180</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Bioeng Transl Med. 2018 Jan 19;3(1):49-57</RefSource>                <PMID Version="1">29376133</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Pharm. 2006 May 11;314(1):83-9</RefSource>                <PMID Version="1">16563671</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mater Sci Eng C Mater Biol Appl. 2015 Nov 1;56:280-5</RefSource>                <PMID Version="1">26249591</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Pharm. 2017 Aug 7;14(8):2697-2710</RefSource>                <PMID Version="1">28704056</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Exp Ther Med. 2017 Sep;14(3):2162-2170</RefSource>                <PMID Version="1">28962137</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Drug Target. 2012 Dec;20(10):813-30</RefSource>                <PMID Version="1">22931500</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Adv Mater. 2018 Apr;30(14):e1706407</RefSource>                <PMID Version="1">29484719</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName>                <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002470" MajorTopicYN="N">Cell Survival</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D003102" MajorTopicYN="N">Colloids</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004317" MajorTopicYN="N">Doxorubicin</DescriptorName>                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D018432" MajorTopicYN="N">Drug Resistance, Multiple</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D019008" MajorTopicYN="N">Drug Resistance, Neoplasm</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006461" MajorTopicYN="N">Hemolysis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D061986" MajorTopicYN="N">MCF-7 Cells</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049329" MajorTopicYN="N">Nanostructures</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009285" MajorTopicYN="N">Naphthoquinones</DescriptorName>                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D055672" MajorTopicYN="N">Static Electricity</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014018" MajorTopicYN="N">Tissue Distribution</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047368" MajorTopicYN="N">Tumor Burden</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">doxorubicin</Keyword>            <Keyword MajorTopicYN="N">multidrug resistance</Keyword>            <Keyword MajorTopicYN="N">nanostructured lipid carriers</Keyword>            <Keyword MajorTopicYN="N">Î²-lapachone</Keyword>        </KeywordList>        <CoiStatement>Disclosure The authors report no conflicts of interest in this work.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>7</Month>                <Day>24</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>18</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30034236</ArticleId>            <ArticleId IdType="doi">10.2147/IJN.S163929</ArticleId>            <ArticleId IdType="pii">ijn-13-4107</ArticleId>            <ArticleId IdType="pmc">PMC6047616</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>